Category News

Zimbabwe Achieves WHO Maturity Level 3 in Medicine Regulation, Joining Africa’s Elite Six

Zimbabwe has reached maturity level 3 (ML 3) in the WHO’s classification of regulatory authorities for medicines, marking a significant achievement in healthcare infrastructure. This classification, assessed using WHO’s Global Benchmarking Tool with over 260 indicators, signifies the establishment of…

Read MoreZimbabwe Achieves WHO Maturity Level 3 in Medicine Regulation, Joining Africa’s Elite Six

Enhancing Clinical Trial Productivity Through AI: Insights from eClinical Solutions at Citeline Roundtable, DIA, and Beyond

eClinical Solutions, a global leader in digital clinical software and services, has announced its participation in several upcoming industry events aimed at advancing biopharma efficiency through its elluminate® platform and biometrics services. These engagements come at a pivotal moment as…

Read MoreEnhancing Clinical Trial Productivity Through AI: Insights from eClinical Solutions at Citeline Roundtable, DIA, and Beyond

CMI Media Group Utilizes KERV Interactive Technology for Introducing ‘Video Attention’ Metrics in Pharmaceutical Advertising

CMI Media Group, a global healthcare media strategy agency and part of WPP (NYSE: WPP), has announced a pioneering partnership with KERV Interactive, a leader in AI-powered video analysis, performance, and monetization. This collaboration introduces innovative ‘Video Attention’ metrics tailored…

Read MoreCMI Media Group Utilizes KERV Interactive Technology for Introducing ‘Video Attention’ Metrics in Pharmaceutical Advertising

Tagrisso Receives US Priority Review for Unresectable Stage III EGFR-Mutated Lung Cancer

AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso has been accepted and granted Priority Review in the US for treating adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT). If…

Read MoreTagrisso Receives US Priority Review for Unresectable Stage III EGFR-Mutated Lung Cancer

Majority of Children with Severe SMA Maintain or Gain Mobility with Genentech’s Evrysdi: 5-Year Data

Genentech, a member of the Roche Group, shared today groundbreaking 5-year findings reaffirming the lasting effectiveness and safety of Evrysdi® (risdiplam) in children diagnosed with Type 1 spinal muscular atrophy (SMA). These insights stem from the open-label extension of the…

Read MoreMajority of Children with Severe SMA Maintain or Gain Mobility with Genentech’s Evrysdi: 5-Year Data

New Clinical Findings Unveiled by Arcturus Therapeutics at the 47th Annual European Cystic Fibrosis Conference

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a global leader in messenger RNA medicines, focused on addressing unmet medical needs in infectious diseases and rare liver and respiratory conditions, unveiled Phase 1 findings in healthy volunteers and interim Phase 1b data…

Read MoreNew Clinical Findings Unveiled by Arcturus Therapeutics at the 47th Annual European Cystic Fibrosis Conference

Helix Unveils Clinico-Genomic Datasets Covering Cardiovascular, Metabolic, Immunology, and Inflammation Disorders

Helix, a prominent population genomics company, has introduced new clinico-genomic datasets aimed at empowering life science firms in advancing precision medicine drug discovery and development. These datasets, cultivated through Helix’s extensive collaborations with health systems, encompass comprehensive longitudinal clinical and…

Read MoreHelix Unveils Clinico-Genomic Datasets Covering Cardiovascular, Metabolic, Immunology, and Inflammation Disorders